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Better together? The promise of multipurpose prevention against sexually transmitted infections, 
unwanted pregnancy, and HIV 
A recent editorial in The Lancet Infectious Diseases “Time to take sexually transmitted infections 
(STIs) seriously” is right to point out the neglect in funding and focus that STIs receive.[1] Far greater 
financial and clinical engagement is needed to reduce the disease burden caused by STIs globally, 
but we argue that a vertical focus will not be an optimal use of limited resources. Instead, we 
encourage an integrated approach to preventing the triumvirate of sexual and reproductive health 
(SRH) issues facing millions of women, particularly in lower- and middle-income countries: STIs, HIV 
and unwanted pregnancy.  
An opportunity to increase overall protection to these SRH threats – by exploiting synergies in 
demand for protection – is emerging with the development of multipurpose prevention technologies 
(MPTs) which offer HIV, STI and pregnancy prevention. Firstly, women with a strong desire for 
contraceptive protection, but weaker (still positive) demand for STI protective protection, could be 
conferred additional STI protection through use of an MPT. Furthermore, research by our group 
indicates that products offering more than one indication will be more much attractive to potential 
users than single purpose products.[2]  
Secondly, low levels of adherence among high-risk younger women in HIV pre-exposure prophylaxis 
trials have raised concerns that current products are not meeting people’s needs.[3] Indeed, there is 
an increasing realisation that multiple prevention options are needed to fit into the varied and 
challenging lifestyles of potential users. Importantly, products offering multipurpose protection have 
been shown to be desirable to potential users, and estimates from a discrete choice experiment 
suggest uptake could be increased three fold among South African women through incorporating STI 
and pregnancy protection.[4]  
MPTs are becoming closer to reality. Products in development include 1) chemical barriers such as 
intravaginal rings or injectable products, 2) physical barriers such as new condoms or cervical caps, 
or 3) a combination of chemical and physical barriers such as a diaphragm used with microbicide gel. 
A vaginal ring is currently undergoing phase-I clinical trials with others soon to follow, whilst co-
administration of contraceptive and HIV prevention products is also under consideration.[5]  
It certainly is time to take STIs seriously. Yet investments in attractive multipurpose products which 
meet a range of SRH needs could have more impact than vertical spending on STIs. Combined with 
existing SRH infrastructures, the whole of multipurpose prevention could be much greater than the 
sum of its parts.  
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